A B C Supplemental Figure S1 SET2 HEL BRD4 β-Actin SET2

Slides:



Advertisements
Similar presentations
Kwee Yong, UCL Cancer Institute
Advertisements

PatientVPA final dose (mg/kg/day) VPA final serum level (mM)(mg/L) Supplemental.
Chapter 8, part B Microbial Genetics.
Chapter 8, part B Microbial Genetics.
From: Gene Regulatory Control of Myocardial Energy Metabolism Predicts Postoperative Cardiac Function in Patients Undergoing Off-pump Coronary Artery Bypass.
A. B. Supplemental Figure S2.  A.  Cell cycle G1/S Growth Factor Regulation.  Publically available data from (20;
Supplementary Table. Gene expression profiling reveals a decrease in NFkB-driven gene signature pattern upon treatment with MLN4924. Gene ID Name Treated/
A Novel Link between Inflammation and Cancer
Volume 21, Issue 12, Pages (December 2017)
Volume 19, Issue 5, Pages (May 2011)
Volume 15, Issue 3, Pages (April 2016)
The Chemopreventive Effect of Tanacetum Polycephalum Against LA7-Induced Breast Cancer in Rats and the Apoptotic Effect of a Cytotoxic Sesquiterpene.
Prolonged early G1 arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle–coupled loss of IRF4 by Xiangao.
by Christopher J. Ott, Nadja Kopp, Liat Bird, Ronald M
Volume 50, Issue 3, Pages (May 2013)
Bortezomib 1nM PU.1 GAPDH KMS12PE U266 U937 Supplemental Figure S1.
Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.
P53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer  Crystal Tonnessen-Murray,
Regulation of Gene Expression
Supplemental Figure S1 B A C D.
BET inhibition and depletion repress the expression of BRCA1 and RAD51
Volume 8, Issue 6, Pages (December 2010)
Volume 22, Issue 3, Pages (September 2012)
Volume 11, Issue 2, Pages (August 2012)
a b MCF-7 TR2 MCF-7 TR2 (Fold change) MTT Assay , (Fold change)
Volume 6, Issue 1, Pages (January 2014)
Supplementary Figure 4 a b c d e f
Volume 58, Issue 6, Pages (June 2015)
Apoptosis-targeted therapies for cancer
Supplementary Figure S1: FGFR4 silencing synergistically enhances the effects of chemotherapy in colon cancer cells. siFGFR4 FGFR4_6 FGFR4_2 Neg Con FGFR4.
Volume 17, Issue 10, Pages (December 2016)
Proliferation of cancer cells despite CDK2 inhibition
Supplemental Figure S1. Gene Granta-519 MAVER-1 JeKo-1 Mino Z-138 ATM
Volume 20, Issue 5, Pages (November 2011)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Dynamic change of transcription pausing through modulating NELF protein stability regulates granulocytic differentiation by Xiuli Liu, Aishwarya A. Gogate,
8 slides for 4 panels (A-D)
BET and MEK inhibition synergistically impair cell cycle regulation and activate apoptotic signaling BET and MEK inhibition synergistically impair cell.
Relative protein levels
Figure 4 Senotherapeutic targeting strategies
MITF upregulation leads to Hsp90i resistance
Volume 9, Issue 6, Pages (December 2017)
Volume 23, Issue 10, Pages (October 2016)
Xiaolong Wei, Hai Xu, Donald Kufe  Cancer Cell 
NM-3 induces p21 levels and down-regulation of Cdk2 activity.
Altered pathways in prostate cancer.
Volume 25, Issue 8, Pages e4 (November 2018)
Volume 21, Issue 2, Pages (October 2017)
Volume 6, Issue 1, Pages (January 2014)
The BRD4 bromodomain is critical for expression of SASP genes.
Volume 24, Issue 6, Pages (December 2013)
Reh cells, 24 hours c-Myc Ac-p53 b-actin
Unraveling the Mysteries of IGF-1 Signaling in Melanoma
Apoptosis-targeted therapies for cancer
John D. Gordan, Craig B. Thompson, M. Celeste Simon  Cancer Cell 
MYC Is a Major Determinant of Mitotic Cell Fate
Supplementary Figure 1 a b c d e
Chapter 8, part B Microbial Genetics.
Volume 18, Issue 9, Pages (February 2017)
Fig. 3. Inactivation of the Wnt/β-catenin signaling pathway inhibited cell proliferation and induced apoptosis in A549 and SPC-A-1 cells. Inactivation.
The CREBBP-modulated network is enriched in signaling pathways upregulated in the light zone (LZ). The CREBBP-modulated network is enriched in signaling.
Fig. 4. Effects of natriuretic peptide receptor 2 (NPR2) knockdown on cells apoptosis in mouse Leydig cells. (A) Relative mRNA expression of cell apoptosis.
Real-time PCR with SYBR Green Master Mix was used to quantify the expression levels of 84 genes ontologically related and regulated by TGF-β /BMP signaling.
Expression data from genes involved in regulation of transit through the cell cycle in response to treatment with E2 and OHT. A. Expression data from genes.
Levels and activity of c-myc are increased in a series of stably transfected DAOY and UW228 medulloblastoma cell lines. Levels and activity of c-myc are.
Interaction of NHEJ and HR pathways in PCO cultures.
HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT signaling. HOXA9 and STAT5 co-occupy similar genomic regions and increase JAK/STAT.
Volume 21, Issue 4, Pages e5 (April 2017)
W. chinensis extract induces apoptosis in AR-dependent prostate cancer cells. W. chinensis extract induces apoptosis in AR-dependent prostate cancer cells.
JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction. JQ1 selectively ablates PAX3–FOXO1-driven transcription and BRD4 interaction.
Presentation transcript:

A B C Supplemental Figure S1 SET2 HEL92.1.7 BRD4 β-Actin SET2 0 100 500 0 100 500 nM, JQ1 BRD4 β-Actin B C SET2 + 10 µM Pomalidomide, 18 hr HEL92.1.7 SET2 50 250 50 250 nM, ARV825, 18 hr 2.5 10 2.5 10 µM, Pomalidomide, 18 hr BRD4 BRD4 BRD2 BRD2 GAPDH GAPDH

Fold Change ARV/Control Supplemental Figure S2 Gene Fold Change ARV/Control P-value Fold Change OTX/Control MYC 0.38 0.0005 0.88 0.286 PIM1 0.14 0.009 0.28 0.058 BCL2 0.32 0.017 0.31 0.057 BCL2L1 (Bcl-xL) 0.33 3.95E-07 0.45 0.0008 LMO2 0.27 0.024 0.073 CTNNB1 1.67 3.44 E-05 1.73 0.0003 CDKN1A 3.21 1.54 0.119 HEXIM1 5.12 5.79E-05 5.32

Reactome_RNA_Pol II_Transcription Reactome_RNA_Pol II_Transcription Supplemental Figure S3 A GSEA with REACTOME PATHWAYS ARV-825 over OTX015 over Control Control REACTOME_TRANSLATION 5.01 4.18 REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION 4.66 3.49 REACTOME_MRNA_PROCESSING 3.01 2.96 REACTOME_TRANSCRIPTION 3 3.51 REACTOME_MRNA_SPLICING 2.88 2.55 REACTOME_RNA_POL_II_TRANSCRIPTION 2.75 2.63   REACTOME_CELL_CYCLE 4.59 4.06 REACTOME_DNA_REPLICATION 3.18 2.93 REACTOME_CHROMOSOME_MAINTENANCE 3.15 3.28 REACTOME_TELOMERE_MAINTENANCE REACTOME_PACKAGING_OF_TELOMERE_ENDS 3.13 3.77 REACTOME_G1_S_TRANSITION 2.73 2.26 REACTOME_CELL_CYCLE_CHECKPOINTS 2.72 2.47 REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT 4.81 3.75 REACTOME_CHOLESTEROL_BIOSYNTHESIS 3.36 2.04 REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS 4.62 3.6 Transcription/ Translation Cell Cycle Energy and Metabolism B Genes induced by ARV825 Genes depleted by ARV-825 NES=2.75 q<0.00025 Enrichment Score Normalized Reactome_RNA_Pol II_Transcription Genes induced by OTX015 Genes depleted NES=2.63 q<0.0011 Enrichment Score Normalized Reactome_RNA_Pol II_Transcription C

Cancer-related pathways Immune system Metabolism Transcription/ Supplemental Figure S4 GSEA with REACTOME PATHWAYS ARV-825 over Control OTX015 over Control REACTOME_SIGNALING_BY_WNT -2.38 -2.2 REACTOME_REGULATION_OF_APOPTOSIS -2.24 -2.15 REACTOME_P53_INDEPENDENT_G1_S_DNA_DAMAGE_CHECKPOINT -2.16 -2.32 REACTOME_GPCR_LIGAND_BINDING -3.73 -3.75 REACTOME_GPCR_DOWNSTREAM_SIGNALING -3.18 -3.37 REACTOME_G_ALPHA_I_SIGNALLING_EVENTS -3.15 -3.5 REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES -3.3 REACTOME_IMMUNE_SYSTEM -2.36 -3.36 REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS -2.33 REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR -2.19 -1.95 REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM -2.42 REACTOME_TCR_SIGNALING -2.14 -2.06 REGULATION_OF_METABOLIC_PROCESS -3.1 -2.18 REGULATION_OF_CELLULAR_METABOLIC_PROCESS -3.01 -2.17 REACTOME_PEPTIDE_HORMONE_BIOSYNTHESIS -2.89 -1.89 REACTOME_GLYCOPROTEIN_HORMONES -2.84 -1.66 REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS -2.69 REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS -2.67 -3.71 REACTOME_NUCLEOTIDE_LIKE_PURINERGIC_RECEPTORS -2.53 -3.05 REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS -2.81 REACTOME_TANDEM_PORE_DOMAIN_POTASSIUM_CHANNELS -1.72 REACTOME_METABOLISM_OF_RNA -3.9 -4.45 REGULATION_OF_RNA_METABOLIC_PROCESS -2.54 -2.07 TRANSCRIPTION -3.32 -2.95 REGULATION_OF_GENE_EXPRESSION -3.03 TRANSLATION -2.46 -3.14 REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS -2.3 -2.4 REACTOME_DESTABILIZATION_OF_MRNA_BY_AUF1_HNRNP_D0 -2.23 REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER -1.82 REACTOME_NUCLEAR_RECEPTOR_TRANSCRIPTION_PATHWAY -1.43 Cancer-related pathways Immune system Metabolism Transcription/ Translation

B A C Supplemental Figure S5 PD-CD34+ sAML PD-CD34+ sAML Control Gene Fold Change ARV/Control P-value Fold change OTX/Control MYC 0.0529 0.045 0.1122 0.0523 IL7R 0.127 0.0292 0.1398 0.0305 CDK6 0.3262 0.0499 0.531 0.1059 BCL2L1 0.1595 0.0087 0.5545 0.0360 STAT5A 0.5931 0.0154 0.5911 0.0152 LMO2 0.2263 0.0053 0.8172 0.1932 BCL2 0.0898 0.083 0.3771 0.172 CTNNB1 2.697 0.0299 2.061 0.087 CDKN1A 5.667 0.0199 1.60 0.040 Control ARV-825 8 hrs Control OTX015 8 hrs 1.2 -1.2 0.0 Down genes 1516 Down genes 685 Up genes 1436 Up genes 713 C PD, CD34+ sAML Down-regulated genes PD, CD34+ sAML Up-regulated genes

D E F G * * * * * * * * * * * † † † † † † † † Supplemental Figure S5 8 hrs

A B SET2 Supplemental Figure S6 Control 250 nM OTX015, 18 hrs -1.6 1.6 1 2 3 1 2 3 c-KIT Axl MUC1 Connexin-43 -1.6 1.6 0.0 Gys pS641 p90 RSK pT573 MAPK pT202/Y204 PKCβ2 pS660 Cl. Caspase 7 Cl. Caspase 3 Histone H3 H2AX pS140 Poly ADP Ribose

A B Supplemental Figure S7 SET2 + 10 µM Pomalidomide, 16 hr 50 250 50 50 250 50 250 nM, ARV-825, 16 hr c-Myc PIM1 Bcl-xL CDK4 p21 GAPDH B

A B PD-CD34+ sAML cells - - + - + Supplemental Figure S8 CD123 CD244 Low Mid High CD123 CD244 CD90 TIM3Fc B BRD4 c-Myc p21 Low Mid High Marker expression p-Rb Control - - + - + 250 nM ARV-825 250 nM OTX015

Supplemental Figure S9 Vehicle vs OTX015 p= 0.021 Vehicle vs ARV-771 p= 0.163

A B D C Supplemental Figure S10 SET2 ARV-825 (nM) ruxolitinib (nM) Fa CI Value 10 50 0.526     0.62536 12    60 0.624     0.52763 14   70 0.631     0.59971 15   75 0.618     0.67435 16 80 0.628     0.69311 18 90 0.693     0.60592 20    100 0.788     0.43825 HEL92.1.7 ARV-825 (nM) ruxolitinib (nM) Fa CI Value 40   200 0.161 0.973 60   300 0.219 0.95793 100  500 0.424 0.55841 120 600 0.528 0.42865 140 700 0.73 0.19797 160   800 0.763 0.18878 1000 0.787 0.20466 D C PD CD34+ sAML ARV-825 (nM) ruxolitinib (nM) Fa CI Value 50 500 0.308 0.45627 60 600 0.339 0.43002 70 700 0.286 0.78349 80 800 0.309 0.72379 90 900 0.381 0.49621 100 1000 0.556 0.26978 PD CD34+ sAML ARV-825 (nM) ruxolitinib (nM) Fa CI value 5 1000 0.134 0.2999 20 0.111 0.87865 50 0.1541 0.15659 100 0.168 0.1078 250 0.179 0.0994

E F G H Supplemental Figure S10 PD CD34+ sAML ARV-825 (nM) ruxolitinib (nM) Fa CI value 2.5 500 0.421 0.15653 5 0.608 0.07797 20 0.812 0.07847 1000 0.412 0.24629 0.756 0.0327 0.856 0.05337 PD CD34+ sAML ARV-825 (nM) ruxolitinib (nM) Fa CI value 5 1000 0.191 0.8348 20 0.237 0.69173 50 0.298 0.55492 100 0.305 0.54654 250 0.326 0.51806 500 0.34 0.50572 G H PD CD34+ sAML ARV-825 (nM) ruxolitinib (nM) Fa CI value 10 500 0.396 0.24943 20 0.435 0.19935 50 0.39 0.50431 100 0.401 0.66261 PD CD34+ sAML ARV-825 (nM) ruxolitinib (nM) Fa CI value 20 1000 0.422 0.90234 50 0.532 0.62104 100 0.566 0.70383 250 0.653 0.61877 500 0.668 0.91967